Quoin Pharmaceuticals (QNRX) Competitors

$5.81 -0.10 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$5.82 +0.01 (+0.17%)

As of 07:01 PM Eastern

QNRX vs. TELA, PSTV, NMTC, CTSO, and STRR

Should you buy Quoin Pharmaceuticals stock or one of its competitors? MarketBeat compares Quoin Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quoin Pharmaceuticals include TELA Bio (TELA), Plus Therapeutics (PSTV), NeuroOne Medical Technologies (NMTC), Cytosorbents (CTSO), and Star Equity (STRR). These companies are all part of the "medical equipment" industry.

How does Quoin Pharmaceuticals compare to TELA Bio?

Quoin Pharmaceuticals (NASDAQ:QNRX) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, valuation, risk, institutional ownership and earnings.

TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 122.22%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of TELA Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Quoin Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

Quoin Pharmaceuticals has a net margin of 0.00% compared to TELA Bio's net margin of -49.30%. Quoin Pharmaceuticals' return on equity of -489.85% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
TELA Bio	-49.30%	-688.50%	-55.77%

In the previous week, TELA Bio had 6 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 8 mentions for TELA Bio and 2 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 1.22 beat TELA Bio's score of 0.03 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TELA Bio	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quoin Pharmaceuticals has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
TELA Bio	$80.28M	0.55	-$38.83M	-$0.79	N/A

Summary

TELA Bio beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Quoin Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Plus Therapeutics has a consensus price target of $58.00, suggesting a potential upside of 906.94%. Given Plus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Plus Therapeutics is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Plus Therapeutics had 4 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Plus Therapeutics and 2 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 1.22 beat Plus Therapeutics' score of 1.06 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quoin Pharmaceuticals has a net margin of 0.00% compared to Plus Therapeutics' net margin of -429.43%. Plus Therapeutics' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
Plus Therapeutics	-429.43%	N/A	-92.28%

Quoin Pharmaceuticals has higher earnings, but lower revenue than Plus Therapeutics. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
Plus Therapeutics	$5.21M	7.58	-$22.39M	-$31.00	N/A

Summary

Plus Therapeutics beats Quoin Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Quoin Pharmaceuticals (NASDAQ:QNRX) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Quoin Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, NeuroOne Medical Technologies has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

NeuroOne Medical Technologies has a consensus price target of $11.67, suggesting a potential upside of 153.62%. Given NeuroOne Medical Technologies' stronger consensus rating and higher possible upside, analysts plainly believe NeuroOne Medical Technologies is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

8.6% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 13.5% of Quoin Pharmaceuticals shares are held by company insiders. Comparatively, 11.8% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, NeuroOne Medical Technologies had 5 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 7 mentions for NeuroOne Medical Technologies and 2 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 1.22 beat NeuroOne Medical Technologies' score of 0.20 indicating that Quoin Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroOne Medical Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Quoin Pharmaceuticals has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -68.35%. NeuroOne Medical Technologies' return on equity of -98.33% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
NeuroOne Medical Technologies	-68.35%	-98.33%	-69.85%

NeuroOne Medical Technologies has higher revenue and earnings than Quoin Pharmaceuticals. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
NeuroOne Medical Technologies	$12.10M	3.28	-$3.61M	-$0.85	N/A

Summary

NeuroOne Medical Technologies beats Quoin Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Cytosorbents has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Quoin Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.92	-$8.20M	-$0.13	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cytosorbents had 4 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 6 mentions for Cytosorbents and 2 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 1.22 beat Cytosorbents' score of -0.22 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quoin Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -191.30% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-191.30%	-36.77%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

Cytosorbents presently has a consensus price target of $5.38, suggesting a potential upside of 892.06%. Given Cytosorbents' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cytosorbents beats Quoin Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Quoin Pharmaceuticals compare to Star Equity?

Star Equity (NASDAQ:STRR) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Star Equity has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Star Equity had 5 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 7 mentions for Star Equity and 2 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 1.22 beat Star Equity's score of -0.02 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Star Equity	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quoin Pharmaceuticals has a net margin of 0.00% compared to Star Equity's net margin of -4.18%. Star Equity's return on equity of -4.04% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Star Equity	-4.18%	-4.04%	-2.40%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

3.8% of Star Equity shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 33.5% of Star Equity shares are owned by company insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Star Equity presently has a consensus price target of $16.50, indicating a potential upside of 65.66%. Given Star Equity's stronger consensus rating and higher probable upside, equities research analysts plainly believe Star Equity is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Star Equity	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Star Equity has higher revenue and earnings than Quoin Pharmaceuticals. Star Equity is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Star Equity	$172.16M	0.21	-$5.92M	-$2.05	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

Summary

Star Equity beats Quoin Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Quoin Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNRX vs. The Competition

Export

Metric	Quoin Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.66M	$3.06B	$6.34B	$12.38B
Dividend Yield	N/A	1.96%	2.80%	5.35%
P/E Ratio	-0.20	13.26	17.79	23.07
Price / Sales	N/A	282.80	549.57	79.28
Price / Cash	N/A	57.78	43.26	56.33
Price / Book	1.20	4.42	9.93	6.96
Net Income	-$15.81M	$72.19M	$3.55B	$333.52M
7 Day Performance	-8.79%	-0.62%	-0.33%	0.45%
1 Month Performance	-7.78%	0.22%	1.34%	4.06%
1 Year Performance	-24.05%	46.24%	41.10%	36.24%

Quoin Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNRX Quoin Pharmaceuticals	0.4396 of 5 stars	$5.81 -1.7%	N/A	-7.1%	$10.66M	N/A	N/A	4	Positive News Earnings Report
TELA TELA Bio	3.1401 of 5 stars	$0.98 -4.4%	$2.20 +125.6%	-2.0%	$42.89M	$80.28M	N/A	120	Earnings Report Gap Down
PSTV Plus Therapeutics	3.0421 of 5 stars	$5.77 -1.3%	$58.00 +904.5%	-67.3%	$39.23M	$5.21M	N/A	20	News Coverage Positive News
NMTC NeuroOne Medical Technologies	4.1318 of 5 stars	$4.59 +4.6%	$13.50 +194.1%	+16.7%	$38.66M	$12.10M	N/A	20	Earnings Report Analyst Downgrade Short Interest Decrease
CTSO Cytosorbents	1.8416 of 5 stars	$0.58 -1.2%	$5.38 +828.3%	-34.4%	$36.30M	$37.06M	N/A	220	News Coverage Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNRX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. TELA, PSTV, NMTC, CTSO, and STRR

How does Quoin Pharmaceuticals compare to TELA Bio?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Summary

How does Quoin Pharmaceuticals compare to Star Equity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quoin Pharmaceuticals (QNRX) Competitors

QNRX vs. TELA, PSTV, NMTC, CTSO, and STRR

How does Quoin Pharmaceuticals compare to TELA Bio?

Do analysts recommend QNRX or TELA?

Do insiders and institutionals have more ownership in QNRX or TELA?

Which has more risk & volatility, QNRX or TELA?

Is QNRX or TELA more profitable?

Does the media refer more to QNRX or TELA?

Which has higher valuation & earnings, QNRX or TELA?

Summary

How does Quoin Pharmaceuticals compare to Plus Therapeutics?

Which has more volatility and risk, QNRX or PSTV?

Do analysts recommend QNRX or PSTV?

Do institutionals and insiders hold more shares of QNRX or PSTV?

Does the media refer more to QNRX or PSTV?

Is QNRX or PSTV more profitable?

Which has stronger valuation and earnings, QNRX or PSTV?

Summary

How does Quoin Pharmaceuticals compare to NeuroOne Medical Technologies?

Which has more volatility and risk, QNRX or NMTC?

Do analysts recommend QNRX or NMTC?

Do institutionals and insiders hold more shares of QNRX or NMTC?

Does the media refer more to QNRX or NMTC?

Is QNRX or NMTC more profitable?

Which has stronger valuation and earnings, QNRX or NMTC?

Summary

How does Quoin Pharmaceuticals compare to Cytosorbents?

Which has more volatility and risk, CTSO or QNRX?

Which has preferable earnings & valuation, CTSO or QNRX?

Do insiders & institutionals hold more shares of CTSO or QNRX?

Does the media prefer CTSO or QNRX?

Is CTSO or QNRX more profitable?

Do analysts rate CTSO or QNRX?

Summary

How does Quoin Pharmaceuticals compare to Star Equity?

Which has more risk and volatility, STRR or QNRX?

Does the media favor STRR or QNRX?

Is STRR or QNRX more profitable?

Do institutionals and insiders have more ownership in STRR or QNRX?

Do analysts prefer STRR or QNRX?

Which has stronger valuation & earnings, STRR or QNRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX vs. The Competition

Quoin Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools